UK: GSK Breathes Easy After Arrow Declaration Success

Last Updated: 20 December 2018
Article by Maherunesa Khandaker

GlaxoSmithKline (GSK) successfully pleaded a Gillette defence and obtained an Arrow declaration in a patent infringement action brought by Vectura in respect of inhalable medicaments - Glaxo Group Ltd & Ors v Vectura Ltd [2018] EWHC 3414 (Pat) (13 December 2018).


Vectura alleged that GSK infringed its patents EP 1 337 240, EP 2 283 817, EP 2 283 818, EP 1 337 241 and EP 1 920 763 (the Patents) for inhalable medicaments by the manufacture and sale of its "Ellipta" dry powder inhalers containing the active ingredients vilanterol and/or umeclidinium to treat asthma and chronic obstructive pulmonary disease.

The Patents claimed methods of making (i) "composite active particles" or (ii) "microparticles" exhibiting delayed dissolution and (iii) such particles obtainable by those methods. The Patents all claimed use of magnesium stearate (MgSt) to form the composite active particles.

GSK denied infringement and claimed revocation, pleading insufficiency and a Gillette defence as its own process was objectively obvious in the light of the prior art. Although GSK's process used MgSt, they submitted this was disclosed by each of the three items of prior art. Additionally, GSK sought an Arrow declaration.

Gillette Defence

Arnold J found GSK's own process was obvious over its pleaded prior art. Although it was not obvious to use vilanterol or umeclidinium as the active at that date, as they were not known actives then, Arnold J found that this did not matter as it was obvious to apply the process to any active suitable for use in a dry powder inhaler.

Additionally, Arnold J found the Patents were insufficient as they did not enable the skilled person to determine that MgSt would be on the surface of the active particles, let alone structurally combined with and fused to them. It followed that Vectura had not established that GSK infringed the Patents.

GSK's claim for an Arrow declaration

At an earlier stage of this case Vectura unsuccessfully attempted to strike out GSK's claim for an Arrow declaration (a declaration that a party has a Gillette defence against claims of infringement of later patents – as discussed in the Fujifilm v AbbVie litigation.. In doing so, Vectura gave an undertaking not to sue GSK under any "Non-Assert Patent" families (a class of patent applications in respect of which GSK had the option to take a licence) as defined in an earlier agreement between the parties.

GSK later identified application EP 2 978 415 ("EP'415") which was not covered by Vectura's undertaking. EP'415 claimed the use of MgSt as a formulation density modifier with umeclidinium and vilanterol as pharmaceutically active material. GSK therefore sought an Arrow declaration for the purposes of commercial certainty and to avoid Vectura reformulating and asserting the inventive concept using applications still on file, relying on EP'415.

Distinguishing Generics v Yeda

In Generics (UK) Ltd v Yeda Research and Development Co Ltd [2017] EWHC 2629 (Pat)Arnold J declined to grant an Arrow declaration as it would not have served a useful purpose beyond his finding that the use of the claimant's product in a particular dosage regimen was obvious at a particular date. Whilst this argument was relied upon by Vectura, Arnold J found this case to differ as Vectura's patents would not necessarily be formulated in a manner leading to the same findings of insufficiency and non-obviousness as in the present case.

The most notable difference however, was Vectura's undertaking to GSK which intended to give GSK comfort that, if they succeeded in defeating Vectura's claims for infringement of the Patents, then GSK would not face further claims for infringement of other patents by the same process and products. Arnold J noted however that Vectura's undertaking did not extend to patents deriving from EP'415 and Vectura did not explain its unwillingness to extend its undertaking to EP'415. It followed that GSK would potentially be at risk of a claim for infringement of a patent deriving from EP'415 and other similarly filed patents.

Arnold J therefore concluded that the grant of an Arrow declaration would serve a useful purpose as it would formalise and confirm the Court's findings with respect to the obviousness of GSK's process and products.

Next steps

Whilst this case was specific to its facts, it highlights the importance of providing a detailed explanation of any caveat or limits to the scope of any undertakings. As such, when drafting an undertaking, it must be drafted in a manner to remove all useful purpose i.e. the scope of a dispute should not be cut down without a full explanation. An absence of such an explanation when drafting the undertakings would be likely to persuade the Court to find there is a useful purpose in granting an Arrow declaration.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions